| Literature DB >> 23344113 |
Maria Filomena de Jesus Raposo1, Rui Manuel Santos Costa de Morais, Alcina Maria Miranda Bernardo de Morais.
Abstract
Marine microalgae have been used for a long time as food for humans, such as Arthrospira (formerly, Spirulina), and for animals in aquaculture. The biomass of these microalgae and the compounds they produce have been shown to possess several biological applications with numerous health benefits. The present review puts up-to-date the research on the biological activities and applications of polysaccharides, active biocompounds synthesized by marine unicellular algae, which are, most of the times, released into the surrounding medium (exo- or extracellular polysaccharides, EPS). It goes through the most studied activities of sulphated polysaccharides (sPS) or their derivatives, but also highlights lesser known applications as hypolipidaemic or hypoglycaemic, or as biolubricant agents and drag-reducers. Therefore, the great potentials of sPS from marine microalgae to be used as nutraceuticals, therapeutic agents, cosmetics, or in other areas, such as engineering, are approached in this review.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23344113 PMCID: PMC3564169 DOI: 10.3390/md11010233
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Applications of marine microalgae biomass, as such, or as extracts.
| Microalgae/Cyanobacteria | Applications | Main Effects/Type of Action | References |
|---|---|---|---|
| human nutrition/health food; liquid CO2 extracts (capsules); potential therapeutic | prebiotic food; antioxidant (extract); anti-allergic, anti-inflammatory (extract) | [ | |
|
| human nutrition/health food and drink supplement; biofertilizer; effluent treatment | growth factor (drink) | [ |
| potential therapeutic (hydrosoluble extract) | anti-inflammatory, analgesic, free radical scavenging | [ | |
| food for bivalves/shellfish | [ | ||
| larvae (aquaculture) | |||
| food for bivalves/shellfish larvae (aquaculture); potential therapeutic | anti-allergic, anti-inflammatory (extract) | [ | |
|
| feed in aquaculture | [ | |
|
| human nutrition (powder); oil extracts with carotenoids (capsules); potential therapeutic | anti-allergic, anti-inflammatory (extract) | [ |
|
| human nutrition | [ | |
|
| potential therapeutic | anti-allergic, anti-inflammatory (extract) | [ |
Marine species of marine microalgae producing EPS.
| Microalgae/Cyanobacteria | Group | Type of Polysaccharide | Main Sugars | References |
|---|---|---|---|---|
|
| diatoms | sPS | xylose, glucose | [ |
|
| sPS | glucose, xylose | ||
|
| EPS (sulphated) | glucose, mannose | [ | |
|
| EPS | [ | ||
|
| EPS | [ | ||
|
| EPS | |||
| EPS | ||||
| EPS | [ | |||
|
| chlorophytes | PS (sulphated) | glucose, xylose | [ |
| sPS | [ | |||
|
| sPS | |||
|
| EPS | |||
| prasinophyte (Chlorophyta) | sPS | |||
| prymnesiophyte/haptophyte | sPS | |||
| rhodophytes | sPS | xylose, galactose | [ | |
|
| sPS | xylose, galactose | [ | |
|
| sPS | [ | ||
|
| sPS | xylose, galactose | [ | |
|
| dinoflagellates | sPS | mannose, galactose | [ |
|
| sPS | galactose | [ | |
|
| cyanophytes | EPS | glucose, fucose | [ |
|
| sPS and intracellular sulphated calcium spirulan (CaSp) | rhamnose, fructose | [ | |
| sPS | [ | |||
EPS, exo- or extracellular polysaccharide; sPS, sulphate containing exopolysaccharide; PS, polysaccharide.
Antiviral applications of EPS from marine microalgae.
| Microalgae/Cyanobacteria | Group | Virus strain | Family/Group of virus | Cell-Lines | EC50/ED50 (μg/mL) | References |
|---|---|---|---|---|---|---|
|
| cyanobacteria | vaccinia virus VACV and VACV-GFP; ectromelia virus (ECTV); HSV-1, HSV-2, human cytomegalovirus (HCMV), measles virus, mumps virus, HIV-1, Flu-A | HEp-2 and Vero C1008; HeLa, HEL, Vero, MDCK | 0.78; 69; 0.92–16.5; 8.3–41; 17–39; 23–92; 2.3–11.4; 9.4–230 | [ | |
| rhodophytes | herpes simplex virus HSV-1 and HSV-2; varicela zoster virus (VZV); murine sarcoma virus (MuSV-124) and MuSV/MuLV (murine leukemia virus) | NIH/3T3 | 1–5 ( | [ | ||
|
| hepatitis B virus (HBV); viral haemorrhagic septicaemia virus (VHSV); African swine fever virus (ASFV); vaccinia virus (VACV); vesicular stomatitis virus (VSV) | HEL | 20, 200 (exocellular extracts); 12–56; 20–45 | [ | ||
|
| vaccinia virus VACV and VACV-GFP; ectromelia virus (ECTV) | HEp-2, Vero C1008 | 0.65 | [ | ||
|
| herpes simplex virus HSV-1 and HSV-2; varicela zoster virus (VZV); murine sarcoma virus (MuSV-124) and MuSV/MuLV (murine leukemia virus) | NIH/3T3 | 10–20; 8; 150 and 50 (RT50) | [ | ||
|
| dinoflagellates | Encephalomyocarditis virus; influenza A virus (Flu-A) | MDCK | 0.19–0.48 | [ | |
|
| Flu-A and Flu-B; respiratory syncytial virus type A (RSV-A) and B (RSV-B); HIV-1; HSV-1; parainfluenza virus type 2 (PFluV-2) | Orthomyxoviridae; | MDCK, Hep-2, MT-4, HMV-2 | 0.45–1.1 and 7.1–8.3; 2.0–3.0 and 0.8; 1.7; 4.52–21.6; 0.8–25.3 | [ |
EC50/ED50 is the concentration/dose at which 50% of the population exhibit a response after being exposed to a certain compound.
Applications, other than antiviral uses, of EPS, from marine microalgae.
| Microalgae/Cyanobacteria | Applications | Cells/Animals used for | References |
|---|---|---|---|
|
| health foods, nutraceutical and functional foods | rats | [ |
| antioxidant and free radical scavenging | 3T3; mouse liver homogenates and erythrocytes haemolysates, sarcoma 180 cells/mice | [ | |
| anti-lipidaemic, antiglycaemic | rats/mice, chickens | [ | |
| anti-inflammatory and immunomodulatory | polymorphonuclear leukocytes/human dermal microvascular endothelial cells, humans; rabbits and sheep (bone joints); mice macrophages/mice and rats | [ | |
| prevention of tumour cell growth | FD early myeloid cell line, 24-1 and EL-4 T-lymphoma cell lines; Graff myeloid cells; rats | [ | |
| anti-adhesive | HeLa S3/sand bass culture cells | [ | |
|
| biolubricant (for bone joints) | [ | |
| ion exchanger | [ | ||
| drag-reducers | [ | ||
Percentages of sulphate, protein, and uronic acids in polysaccharides from different marine microalgae.
| Microalgae/Cyanobacteria | Sulphate (%) | Protein (%) | Uronic acids (%) | References |
|---|---|---|---|---|
| 7.6–14.6 | 1–2 | 7.8–10 | [ | |
| 8 | 6 | 5–7.8 | [ | |
|
| 5–20 | 6 | 7 | [ |
|
| 7.8–9.4 | 3.7–9.0 | [ | |
|
| 7.5–13.3 | 1.4–6.3 | [ | |
|
| 0–10.9 | 7.7–9.2 | 4.8–21.0 | [ |
|
| 6.3–11.5 | 0.5–4.9 | 7.7–8.0 | [ |
|
| 7–8 | presence, without % | [ | |
|
| 10.3 | 2.9 | [ |